A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Sponsor

AstraZeneca (Industry)

Overall Status

Recruiting

CT.gov ID

NCT05104866

Collaborator

Daiichi Sankyo, Inc. (Industry)

700

Enrollment

239

Locations

Arms

Anticipated Duration (Months)

2.9

Patients Per Site

0.1

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The study will evaluate the safety and efficacy of datopotamab deruxtecan (also known as Dato-DXd, DS-1062a), when compared with Investigator's choice of standard of care single-agent chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Drug: Dato-DXd Drug: Capecitabine Drug: Gemcitabine Drug: Eribulin Drug: Vinorelbine	Phase 3

Detailed Description

The primary objective of this study will assess the safety and efficacy of datopotamab deruxtecan (Dato-DXd) in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer who have been treated with one or two prior lines of systemic chemotherapy.

The study will be stratified based on number of previous lines of chemotherapy (1 vs. 2), prior use of CDK4/6 inhibitors (Yes vs. no) and geographic region of participant (US/Canada/Europe vs. rest of world).

This study aims to see if datopotamab deruxtecan allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

700 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

ParallelParallel

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Actual Study Start Date :

Oct 18, 2021

Anticipated Primary Completion Date :

Jul 18, 2025

Anticipated Study Completion Date :

Jul 18, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Dato-DXd Arm 1: Dato-DXd	Drug: Dato-DXd Experimental drug. Provided in 100mg vials. IV infusion. Other Names: Datopotamab deruxtecan (Dato-DXd, DS-1062a)
Active Comparator: Investigators Choice of Chemotherapy (ICC) Arm 2: ICC Capecitabine Gemcitabine Eribulin mesylate Vinorelbine	Drug: Capecitabine Tablet. Oral route of administration. Active comparator Drug: Gemcitabine IV Infusion. Active comparator Drug: Eribulin IV Infusion. Active comparator Other Names: Eribulin Mesylate Drug: Vinorelbine IV Infusion. Active comparator

Arm

Intervention/Treatment

Experimental: Dato-DXd

Arm 1: Dato-DXd

Drug: Dato-DXd

Experimental drug. Provided in 100mg vials. IV infusion.

Other Names:

Datopotamab deruxtecan (Dato-DXd, DS-1062a)

Active Comparator: Investigators Choice of Chemotherapy (ICC)

Arm 2: ICC Capecitabine Gemcitabine Eribulin mesylate Vinorelbine

Drug: Capecitabine

Tablet. Oral route of administration. Active comparator

Drug: Gemcitabine

IV Infusion. Active comparator

Drug: Eribulin

IV Infusion. Active comparator

Other Names:

Eribulin Mesylate

Drug: Vinorelbine

IV Infusion. Active comparator

Outcome Measures

Primary Outcome Measures

Progression Free Survival [From randomization until progression as assessed by BICR or death due to any cause (anticipated to be 21 months after the first participant has been randomized)]
PFS is defined as time from randomization until progression per RECIST 1.1, as assessed by BICR, or death due to any cause. The analysis will include all randomized participants as randomized regardless of whether the participant withdraws from therapy, receives another anti-cancer therapy, or clinically progresses prior to RECIST 1.1. The measure of interest is the hazard ratio of PFS.
Overall Survival [Approximately 44 months after the first participant has been randomized]
OS is defined as time from randomization until the date of death due to any cause. The comparison will include all randomized participants as randomized, regardless of whether the participant withdraws from therapy or receives another anti-cancer therapy. The measure of interest is the hazard ratio of OS.

Secondary Outcome Measures

Objective Response Rate (ORR) [Randomization to event (response, progression, last evaluable assessment) anticipated to be up to 21 months]
Objective response rate is defined as the proportion of participants who have a confirmed CR or PR, as determined by the BICR/Investigator assessment, per RECIST 1.1.
Duration of Response (DoR) [From randomization to event up to 21 months; from date of first response until progression or death up to 20 months]
Duration of response is defined as the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1, as assessed by BICR/Investigator assessment or death due to any cause.
Progression-Free Survival by Investigator assessment [From randomization to progression (investigator assessment) or death (anticipated to be up to 21 months)]
PFS by Investigator assessment will be defined as the time from the date of randomization until the date of PD per RECIST 1.1 (by Investigator assessment) or death (by any cause in the absence of progression), (ie, date of event or censoring - date of randomization + 1).
Disease Control Rate (DCR) [At least 11 weeks after randomization up to 18 months.]
Disease control rate at 12 weeks is defined as the percentage of participants who have a confirmed CR or PR or who have SD, per RECIST 1.1, as assessed BICR/per investigator assessment and derived from the raw tumor data for at least 11 weeks after randomization.
Time to First Subsequent Therapy (TFST) [From randomization to start of first subsequent anti-cancer therapy post discontinuation of randomized treatment (anticipated to be up to 21 months)]
Time to first subsequent therapy is defined as the time from randomization until the start date of the first subsequent anti-cancer therapy after discontinuation of randomized treatment, or death due to any cause.
Time to Second Subsequent Therapy (TSST) [From randomization to start of second subsequent anti-cancer therapy post discontinuation of first subsequent therapy (anticipated to be up to 21 months)]
Time to second subsequent therapy is defined as the time from randomization to until the start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment, or death due to any cause.
Time from randomization to second progression or death (PFS2) [From randomization to second progression or death (anticipated to be up to 21 months)]
Time to second progression of death will be defined as the time from the randomization to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the Investigator in the eCRF and defined according to local standard clinical practice.
Clinical Outcome Assessment- TTD in pain [From randomization to 18 weeks post-progression]
The secondary PRO endpoints include: TTD in pain as measured by the pain scale from EORTC QLQ-C30
Pharmacokinetics of Dato-DXd [From first dose to end of treatment (anticipated to be up to 21 months).]
Plasma concentrations of Dato-DXd, total anti-TROP2 antibody, and MAAA-1181a (payload).
Immunogenicity [From first dose to end of treatment safety follow-up (anticipated to be up to 22 months).]
To test for the presence of ADA to investigate the immunogenicity of Dato-DXd.
Clinical Outcome Assessment- TTD in physical Functioning [From randomization to 18 weeks post-progression]
The secondary PRO endpoints include: TTD in physical functioning as measured by the physical functioning scale from EORTC QLQ-C30
Clinical Outcome Assessment- TTD in GHS [From randomization to 18 weeks post-progression]
The secondary PRO endpoints include: TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC QLQ-C30

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria

Age • Participant must be ≥ 18 years at the time of screening.

Type of Participant and Disease Characteristics

Inoperable or metastatic HR+, HER2-negative breast cancer
Progressed on and not suitable for endocrine therapy per investigator assessment and treated with 1 to 2 lines of prior chemotherapy in the inoperable/metastatic setting. Participant must have documented progression on their most recent line of chemotherapy.
Eligible for one of the chemotherapy options listed as ICC (eribulin, capecitabine, vinorelbine, gemcitabine), per investigator assessment.
ECOG PS of 0 or 1, with no deterioration over the previous 2 weeks prior to day of first dosing.
At least 1 measurable lesion not previously irradiated that qualifies as a RECIST 1.1. Note: Participants with bone-only metastases are not permitted.
Participants with a history of previously treated neoplastic spinal cord compression, or clinically inactive brain metastases, who require no treatment with corticosteroids or anticonvulsants, may be included in the study, if they have recovered from the acute toxic effect of radiotherapy. A minimum of 2 weeks must have elapsed between the end of radiotherapy and study enrolment.
Adequate organ and bone marrow function within 7 days before day of first dosing as follows:
Hemoglobin: ≥ 9.0 g/L.
Absolute neutrophil count: 1500/mm3.
Platelet count: 100000/mm3. • Total bilirubin: ≤ 1.5 × ULN if no liver metastases; or ≤ 3 × ULN in the presence of documented Gilbert's syndrome (unconjugated hyperbilirubinemia) or liver metastases at baseline.
ALT and AST: ≤ 3 × ULN for AST/ALT; however, if elevation is due to liver metastases, ≤ 5.0 × ULN is allowed.
Calculated creatinine clearance: ≥ 30 mL/min as calculated using the Cockcroft-Gault equation (using actual body weight).
LVEF ≥ 50% by either an echocardiogram or MUGA within 28 days of first dosing.
Has had an adequate treatment washout period before Cycle 1 Day 1, defined as:
Major surgery: ≥ 3 weeks.
Radiation therapy including palliative radiation to chest: ≥ 4 weeks (palliative radiation therapy to other areas ≥ 2 weeks).
Anticancer therapy including hormonal therapy: ≥ 3 weeks (for small molecule targeted agents: ≥ 2 weeks or 5 half-lives, whichever is longer).
Antibody-based anticancer therapy: ≥ 4 weeks with the exception of receptor activator of nuclear factor kappa-B ligand (RANKL) inhibitors (eg, denosumab for the treatment of bone metastases).
Immunotherapy (non-antibody-based therapy): ≥ 2 weeks or 5 times the terminal elimination T½ of the agent, whichever is longer.
Chloroquine/hydroxychloroquine: > 14 days.
Have available a FFPE tumor sample (block preferred, or a minimum of 20 freshly cut slides), at the time of screening. Note: Sample collection in China will comply with local regulatory approval.
Minimum life expectancy of 12 weeks at screening.

Sex

• Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies; (oral estrogens are not permitted).

Reproduction

Negative pregnancy test (serum) for women of childbearing potential
Female participants must be post-menopausal for at least 1 year, surgically sterile, or using one highly effective form of birth control. Female participants must refrain from egg cell donation and breastfeeding while on study and for at least 7 months after the last dose of study intervention. Non-sterilized male partners of a woman of childbearing potential must use a male condom plus spermicide throughout this period.
Male participants who intend to be sexually active with a female partner of childbearing potential must be surgically sterile or using a highly effective method of contraception from the time of screening throughout the total duration of the study and the drug washout period (at least 4 months after the last dose of study intervention) to prevent pregnancy in a partner. Male participants must not donate or bank sperm during this same time period. Not engaging in heterosexual activity (sexual abstinence) for the duration of the study and drug washout period is an acceptable practice if this is the preferred usual lifestyle of the participant; however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Female partners of male participants are allowed to use HRT for contraception.

Informed Consent

Capable of giving signed informed consent.
Provision of signed and dated written Optional Genetic Research Information informed consent prior to collection of sample for optional genetic research that supports Genomic Initiative.

Exclusion Criteria

Medical Conditions

Any evidence of diseases which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.
History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 3 years before the first dose of study intervention and of low potential risk for recurrence. Exceptions include basal cell carcinoma of the skin and squamous cell carcinoma of the skin that has undergone potentially curative therapy, adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other solid tumors curatively treated.
Persistent toxicities caused by previous anticancer therapy (excluding alopecia), not yet improved to CTCAE Version 5.0 Grade ≤ 1 or baseline. Note: participants may be enrolled with some chronic, stable Grade 2 toxicities (defined as no worsening to > Grade 2 for at least 3 months prior to first dosing and managed with SoC treatment) which the investigator deems related to previous anticancer therapy.
Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals; suspected infections (eg, prodromal symptoms); or inability to rule out infections.
Known active or uncontrolled hepatitis B or C infection; or positive for hepatitis B or C virus based on the evaluation of results of tests for hepatitis B (HBsAg, anti-HBs, anti-HBc, or HBV DNA) or hepatitis C (HCV antibody or HCV RNA) infection at screening.
Known HIV infection that is not well controlled.
Uncontrolled or significant cardiac disease, including myocardial infarction or uncontrolled/unstable angina within 6 months prior to C1D1, CHF (New York Heart Association Class II to IV), uncontrolled or significant cardiac arrhythmia, or uncontrolled hypertension (resting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg).
Investigator judgment of 1 or more of the following:
Mean resting corrected QTcF interval > 470 ms , obtained from triplicate ECGs performed at screening.
History of QT prolongation associated with other medications that required discontinuation of that medication, or any current concomitant medication known to prolong the QT interval and cause Torsades de Pointes.
Congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in first-degree relatives.
History of (non-infectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with pulmonary involvement, or prior pneumonectomy.
Leptomeningeal carcinomatosis.
Clinically significant corneal disease.
Known active tuberculosis infection

Prior/Concomitant Therapy

Any of the following prior anticancer therapies:
Any treatment (including ADC) containing a chemotherapeutic agent targeting topoisomerase I
TROP2-targeted therapy
Prior treatment with same ICC agent
Any concurrent anticancer treatment, with the exception of bisphosphonates, denosumab, for the treatment of bone metastases.
Concurrent use of systemic hormonal replacement therapy (eg, estrogen). However, concurrent use of hormones for non-cancer related conditions (eg, insulin for diabetes) is acceptable.
Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 3 weeks of the first dose of study intervention or an anticipated need for major surgery during the study.
Receipt of live, attenuated vaccine within 30 days prior to the first dose of study treatment.

Prior/Concurrent Clinical Study Experience

Previous treatment in the present study.
Participation in another clinical study with a study intervention or investigational medicinal device administered in the last 4 weeks prior to first dosing, randomization into a prior Dato-DXd or T-DXd (trastuzumab deruxtecan) study regardless of treatment assignment, or concurrent enrolment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study.
Participants with a known hypersensitivity to Dato-DXd, or any of the excipients of the product (including, but not limited to, polysorbate 80).
Known history of severe hypersensitivity reactions to other monoclonal antibodies.

Other Exclusions

Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
Judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions and requirements.
For women only, currently pregnant (confirmed with positive pregnancy test) or breastfeeding, or who are planning to become pregnant.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	Duarte	California	United States	91010
2	Research Site	Los Angeles	California	United States	90095
3	Research Site	Palo Alto	California	United States	94305-5826
4	Research Site	San Francisco	California	United States	94143
5	Research Site	Fort Myers	Florida	United States	33901
6	Research Site	Jacksonville	Florida	United States	32207
7	Research Site	West Palm Beach	Florida	United States	33401
8	Research Site	Atlanta	Georgia	United States	30322
9	Research Site	Chicago	Illinois	United States	60637
10	Research Site	Boston	Massachusetts	United States	02114
11	Research Site	Boston	Massachusetts	United States	02215
12	Research Site	Boston	Massachusetts	United States	02215
13	Research Site	Grand Rapids	Michigan	United States	49503
14	Research Site	Jackson	Mississippi	United States	39216
15	Research Site	Kansas City	Missouri	United States	64111
16	Research Site	Ridgewood	New Jersey	United States	07450
17	Research Site	New York	New York	United States	10065
18	Research Site	Charlotte	North Carolina	United States	28204
19	Research Site	Cleveland	Ohio	United States	44119
20	Research Site	Columbus	Ohio	United States	43219
21	Research Site	Portland	Oregon	United States	97239
22	Research Site	Pittsburgh	Pennsylvania	United States	15213
23	Research Site	Providence	Rhode Island	United States	02906
24	Research Site	Nashville	Tennessee	United States	37203
25	Research Site	Nashville	Tennessee	United States	37232
26	Research Site	El Paso	Texas	United States	79905
27	Research Site	Houston	Texas	United States	77030
28	Research Site	Richmond	Virginia	United States	23219
29	Research Site	Madison	Wisconsin	United States	53792
30	Research Site	Caba		Argentina	1414
31	Research Site	Caba		Argentina	C1280AEB
32	Research Site	La Plata		Argentina	1900
33	Research Site	Mar del Plata		Argentina	7600
34	Research Site	Rosario		Argentina	2123
35	Research Site	Rosario		Argentina	S2000DEJ
36	Research Site	San Salvador de Jujuy		Argentina	4600
37	Research Site	Anderlecht		Belgium	1070
38	Research Site	Leuven		Belgium	3000
39	Research Site	Liège		Belgium	4000
40	Research Site	Brasília		Brazil	70200-730
41	Research Site	Jau		Brazil	17210-080
42	Research Site	Porto Alegre		Brazil	90035903
43	Research Site	Porto Alegre		Brazil	90610-000
44	Research Site	Ribeirão Preto		Brazil	14051-140
45	Research Site	Rio de Janeiro		Brazil	20560-120
46	Research Site	Santa Catarina		Brazil	88301-220
47	Research Site	Sao Paulo		Brazil	01236-030
48	Research Site	Sao Paulo		Brazil	01246-000
49	Research Site	Sao Paulo		Brazil	01509-900
50	Research Site	Sao Paulo		Brazil	1323001
51	Research Site	São Paulo		Brazil	03102-002
52	Research Site	São Paulo		Brazil	04538-132
53	Research Site	Edmonton	Alberta	Canada	T6G 1Z2
54	Research Site	North Vancouver	British Columbia	Canada	V7L 2L7
55	Research Site	Vancouver	British Columbia	Canada	V5Z 4E6
56	Research Site	Moncton	New Brunswick	Canada	E1C 6Z8
57	Research Site	Halifax	Nova Scotia	Canada	B3H 2Y9
58	Research Site	North York	Ontario	Canada	M2K 1E1
59	Research Site	Toronto	Ontario	Canada	M5G 2M9
60	Research Site	Montreal	Quebec	Canada	H4A 3J1
61	Research Site	Ste-Foy	Quebec	Canada	G1V 4G2
62	Research Site	Montreal		Canada	H3T 1E2
63	Research Site	Baoding		China	071000
64	Research Site	Beijing		China	100044
65	Research Site	Beijing		China	100071
66	Research Site	Beijing		China	100210
67	Research Site	Bengbu		China	233060
68	Research Site	Changchun		China	130021
69	Research Site	Changsha		China	410008
70	Research Site	Changsha		China	410013
71	Research Site	Chengdu		China	610000
72	Research Site	Dalian		China	116001
73	Research Site	Guangzhou		China	510060
74	Research Site	Hangzhou		China	310003
75	Research Site	Hangzhou		China	310020
76	Research Site	Hangzhou		China	310022
77	Research Site	Harbin		China	150049
78	Research Site	Jinan		China	250001
79	Research Site	Jinan		China	2501117
80	Research Site	Linyi		China	276000
81	Research Site	Nanchang		China	330006
82	Research Site	Nanchang		China	330009
83	Research Site	Nanjing		China	210029
84	Research Site	Nantong		China	226001
85	Research Site	Shanghai		China	200000
86	Research Site	Shanghai		China	200025
87	Research Site	Shanghai		China	200032
88	Research Site	Shenyang		China	110001
89	Research Site	Shenyang		China	110016
90	Research Site	Tianjin		China	300060
91	Research Site	Xiamen		China	361003
92	Research Site	Xian		China	710100
93	Research Site	Zhengzhou		China	450008
94	Research Site	Zhengzhou		China
95	Research Site	Bordeaux		France	33030
96	Research Site	Lille cedex		France	59020
97	Research Site	Lyon Cedex 08		France	69373
98	Research Site	Montpellier		France	34070
99	Research Site	Plerin		France	22190
100	Research Site	Reims		France	51100
101	Research Site	Toulouse Cedex 9		France	31059
102	Research Site	Villejuif		France	94800
103	Research Site	Aschaffenburg		Germany	63739
104	Research Site	Essen		Germany	45147
105	Research Site	Heidelberg		Germany	69120
106	Research Site	Homburg		Germany	66421
107	Research Site	Leipzig		Germany	4103
108	Research Site	Lübeck		Germany	23538
109	Research Site	München		Germany	80637
110	Research Site	München		Germany	81675
111	Research Site	Ravensburg		Germany	88212
112	Research Site	Rostock		Germany	18147
113	Research Site	Budapest		Hungary	1062
114	Research Site	Budapest		Hungary	1122
115	Research Site	Győr		Hungary	9024
116	Research Site	Miskolc		Hungary	3526
117	Research Site	Szekszárd		Hungary	7100
118	Research Site	Szolnok		Hungary	5004
119	Research Site	Coimbatore		India	641005
120	Research Site	Gulbarga		India	585105
121	Research Site	Gurgaon		India	122001
122	Research Site	Howrah		India	711103
123	Research Site	Hyderabad		India	500082
124	Research Site	JAipur		India	302022
125	Research Site	Kolkata		India	700160
126	Research Site	Ludhiana		India	141002
127	Research Site	Nashik		India	422009
128	Research Site	Nashik		India	422011
129	Research Site	Rishikesh		India	249203
130	Research Site	Surat		India	395002
131	Research Site	Vishakhapatnam		India	530017
132	Research Site	Ancona		Italy	60123
133	Research Site	Bologna		Italy	40138
134	Research Site	Candiolo		Italy	10060
135	Research Site	Firenze		Italy	50139
136	Research Site	Meldola		Italy	47014
137	Research Site	Milano		Italy	20132
138	Research Site	Milan		Italy	20141
139	Research Site	Napoli		Italy	80131
140	Research Site	Padova		Italy	35128
141	Research Site	Prato		Italy	59100
142	Research Site	Roma		Italy	00168
143	Research Site	Chuo-ku		Japan	104-0045
144	Research Site	Fukuoka		Japan	811-1395
145	Research Site	Fukushima-shi		Japan	960-1295
146	Research Site	Hiroshima-shi		Japan	730-8518
147	Research Site	Isehara-shi		Japan	259-1193
148	Research Site	Kagoshima-shi		Japan	892-0833
149	Research Site	Kashiwa		Japan	227-8577
150	Research Site	Kitaadachi-gun		Japan	362-0806
151	Research Site	Koto-ku		Japan	135-8550
152	Research Site	Kyoto-shi		Japan	606-8507
153	Research Site	Matsuyama-shi		Japan	791-0280
154	Research Site	Nagoya-shi		Japan	464-8681
155	Research Site	Nishinomiya-shi		Japan	663-8501
156	Research Site	Okayama-shi		Japan	700-8558
157	Research Site	Osaka-shi		Japan	541-8567
158	Research Site	Osakasayama-shi		Japan	589-8511
159	Research Site	Sapporo-shi		Japan	003-0804
160	Research Site	Shinagawa-ku		Japan	142-8666
161	Research Site	Shinjuku-ku		Japan	162-8655
162	Research Site	Yokohama-shi		Japan	241-8515
163	Research Site	Goyang-si		Korea, Republic of	410-769
164	Research Site	Seoul		Korea, Republic of	02841
165	Research Site	Seoul		Korea, Republic of	03080
166	Research Site	Seoul		Korea, Republic of	03722
167	Research Site	Seoul		Korea, Republic of	06273
168	Research Site	Seoul		Korea, Republic of	06351
169	Research Site	Seoul		Korea, Republic of	138-736
170	Research Site	Estado de México		Mexico	50080
171	Research Site	Guadalajara		Mexico	44280
172	Research Site	Nuevo Leon		Mexico	66278
173	Research Site	Toluca		Mexico	50180
174	Research Site	Amsterdam		Netherlands	1081 HV
175	Research Site	Rotterdam		Netherlands	3083 AN
176	Research Site	Venlo		Netherlands	5912 BL
177	Research Site	Białystok		Poland	15-027
178	Research Site	Gdansk		Poland	80-952
179	Research Site	Gdynia		Poland	81-519
180	Research Site	Konin		Poland	62-500
181	Research Site	Koszalin		Poland	75-581
182	Research Site	Poznan		Poland	61-866
183	Research Site	Rzeszów		Poland	30-055
184	Research Site	Tomaszów Mazowiecki		Poland	97-200
185	Research Site	Toruń		Poland	87-100
186	Research Site	Warszawa		Poland	02-781
187	Research Site	Łódź		Poland	90-302
188	Research Site	Kazan		Russian Federation	420029
189	Research Site	Krasnoyarsk		Russian Federation	660133
190	Research Site	Moscow		Russian Federation	111123
191	Research Site	Moscow		Russian Federation	115478
192	Research Site	Moscow		Russian Federation	121205
193	Research Site	Moscow		Russian Federation	143423
194	Research Site	Moscow		Russian Federation	143442
195	Research Site	Nizhny Novgorod		Russian Federation	603126
196	Research Site	Saint Petersburg		Russian Federation	190020
197	Research Site	Saint Petersburg		Russian Federation	197758
198	Research Site	Saint-Petersburg		Russian Federation	196603
199	Research Site	Amanzimtoti		South Africa	4126
200	Research Site	Cape Town		South Africa	7570
201	Research Site	George		South Africa	6529
202	Research Site	Johannesburg		South Africa	2196
203	Research Site	Port Elizabeth		South Africa	6045
204	Research Site	Pretoria		South Africa	0002
205	Research Site	Pretoria		South Africa	0081
206	Research Site	Pretoria		South Africa	0181
207	Research Site	Rondebosch		South Africa	7700
208	Research Site	Barcelona		Spain	08028
209	Research Site	Barcelona		Spain	08036
210	Research Site	Bilbao (Vizcaya)		Spain	48013
211	Research Site	Huelva		Spain	21005
212	Research Site	L'Hospitalet de Llobregat		Spain	08908
213	Research Site	La Coruña		Spain	15006
214	Research Site	Madrid		Spain	28034
215	Research Site	Madrid		Spain	28040
216	Research Site	Malaga		Spain	29010
217	Research Site	Sevilla		Spain	41013
218	Research Site	Valencia		Spain	46010
219	Research Site	Kaohsiung		Taiwan	824
220	Research Site	Kaohsiung		Taiwan	833
221	Research Site	Taichung		Taiwan	40447
222	Research Site	Tainan		Taiwan	70403
223	Research Site	Taipei City		Taiwan	10050
224	Research Site	Taipei		Taiwan	10449
225	Research Site	Taipei		Taiwan	11217
226	Research Site	Taoyuan		Taiwan	333
227	Research Site	Blackpool		United Kingdom	FY3 8NR
228	Research Site	Bristol		United Kingdom	BS2 8ED
229	Research Site	Cardiff		United Kingdom	CF14 2TL
230	Research Site	Colchester		United Kingdom	CO4 5JL
231	Research Site	Derry		United Kingdom	BT47 6SB
232	Research Site	Edinburgh		United Kingdom	EH4 2XU
233	Research Site	Guildford		United Kingdom	GU2 7WG
234	Research Site	London		United Kingdom	EC1A 7BE
235	Research Site	London		United Kingdom	SW3 6JJ
236	Research Site	Manchester		United Kingdom	M20 4BX
237	Research Site	Nottingham		United Kingdom	NG5 1PB
238	Research Site	Sutton		United Kingdom	SM2 5PT
239	Research Site	Truro		United Kingdom	TR1 3LJ